SCHEMBL3535832

SCHEMBL3535832

Cn1c(-c2n[nH]c3cc(OCc4ccccc4)c(OCc4ccccc4)cc23)nc2ccccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.45
PTGES O14684 1/20 0.43
RAB9A P51151 4/20 0.42
NPC1 O15118 3/20 0.42
STAT3 P40763 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MAPT P10636 1/20 0.42
KDR P35968 1/20 0.41
MAPK1 P28482 2/20 0.41
KDM4E B2RXH2 2/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
PAX8 Q06710 1/20 0.40
CSF1R P07333 1/20 0.39
RHEB Q15382 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3540087 0.96 ABL1 (0.49) ABL1PTGESRAB9ACSF1RCTSV
SCHEMBL3534761 0.86 PTGES (0.48) ABL1PTGESRAB9ANPC1SMN1; SMN2
SCHEMBL3533928 0.84 ADORA1 (0.44) RAB9ANPC1HTTSMN1; SMN2MAPT
SCHEMBL3538596 0.84 ABL1 (0.44) ABL1PTGESMAPTKDM4EGAA
SCHEMBL3535167 0.83 RAB9A (0.45) PTGESRAB9ANPC1STAT3HTT
SCHEMBL3536967 0.83 ABL1 (0.52) ABL1RAB9ANPC1MAPK1ALDH1A1
SCHEMBL3533624 0.80 ABL1 (0.55) ABL1RAB9ANPC1HTTMAPK1
SCHEMBL3541944 0.77 KDM4E (0.46) RAB9ANPC1HTTSMN1; SMN2MAPT
SCHEMBL3538710 0.75 CHEK2 (0.45) ABL1RAB9ANPC1HTTSMN1; SMN2
SCHEMBL3542920 0.74 PTGES (0.47) ABL1PTGESRAB9ANPC1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK ABL1 1/4885PTGES 4588/4885RAB9A 2461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.